The Future of metabolic health and weight loss drugs : projecting mortality reductions in the US and UK populations

<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<rdf:Description>
<dc:creator>Swiss Re Institute</dc:creator>
<dc:creator>Swiss Re Institute</dc:creator>
<dc:date>2025</dc:date>
<dc:description xml:lang="es">Sumario: The widespread use of GLP-1 weight loss drugs to treat obesity could significantly reduce cumulative all-cause mortality by 2045up to 6.4% in the US and 5.1% in the UKaccording to the modelling presented. These reductions are expected to come primarily from lower cardiovascular disease (CVD) mortality and improved outcomes in other conditions, assuming clinical trial results translate into real-world effectiveness. This has major implications for life and health insurers, potentially reshaping claims and lowering costs for longevity-related products. However, GLP-1 drugs have not yet demonstrated long-term improvements in population-level metabolic health. The US, with the highest adult obesity rate among developed countries (40.3%), is projected to exceed 55% by 2050 without intervention. GLP-1 drugs like semaglutide and tirzepatide have shown substantial weight loss in trials, but real-world effectiveness may vary. In baseline projections, mortality reductions are 4% (US) and 3.2% (UK), while pessimistic scenarios suggest smaller impacts (2.3% and 1.8%). Risks include discontinuation due to lack of lifestyle support and concerns over muscle and bone loss. For insurers, while mortality and critical illness portfolios may benefit, longevity portfolios could face financial pressure due to longer lifespans and extended pension payouts</dc:description>
<dc:identifier>https://documentacion.fundacionmapfre.org/documentacion/publico/es/bib/188363.do</dc:identifier>
<dc:language>eng</dc:language>
<dc:publisher>Swiss Re Institute</dc:publisher>
<dc:rights xml:lang="es">InC - http://rightsstatements.org/vocab/InC/1.0/</dc:rights>
<dc:subject xml:lang="es">Salud</dc:subject>
<dc:subject xml:lang="es">Obesidad</dc:subject>
<dc:subject xml:lang="es">Productos farmacéuticos</dc:subject>
<dc:subject xml:lang="es">Proyecciones</dc:subject>
<dc:subject xml:lang="es">Tablas de mortalidad</dc:subject>
<dc:subject xml:lang="es">Riesgo cardiovascular</dc:subject>
<dc:subject xml:lang="es">Vigilancia de la salud</dc:subject>
<dc:subject xml:lang="es">Seguro de salud</dc:subject>
<dc:subject xml:lang="es">Estados Unidos</dc:subject>
<dc:subject xml:lang="es">Reino Unido</dc:subject>
<dc:type xml:lang="es">Books</dc:type>
<dc:title xml:lang="es">The Future of metabolic health and weight loss drugs : projecting mortality reductions in the US and UK populations</dc:title>
<dc:format xml:lang="es">23 p.</dc:format>
<dc:coverage xml:lang="es">Estados Unidos</dc:coverage>
<dc:coverage xml:lang="es">Reino Unido</dc:coverage>
<dc:description xml:lang="es">Metabolic ill-health and mortality -- Metabolic ill-health trends: the US and UK -- GLP-1 drugs and mortality reductions: our modelling approach -- The US and UK 2045 mortality reduction projections -- Risks associated with GLP-1 drugs -- Implications for L&H insurance -- Swiss Re's vision of metabolic health</dc:description>
</rdf:Description>
</rdf:RDF>